Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 468 Neoplasms 332 Colorectal Neoplasms 235 Carcinoma, Non-Small-Cell Lung 235 Lung Neoplasms 200 Prostatic Neoplasms 182 Carcinoma, Hepatocellular 175 Stomach Neoplasms 138 Pancreatic Neoplasms 126 Leukemia, Myeloid, Acute 115 Uterine Cervical Neoplasms 111 Rectal Neoplasms 103 Multiple Myeloma 94 Recurrence 89 Squamous Cell Carcinoma of Head and Neck 84 Head and Neck Neoplasms 80 Ovarian Neoplasms 78 Neoplasm Metastasis 77 Brain Neoplasms 71 Colonic Neoplasms 68 Glioblastoma 67 Esophageal Neoplasms 66 Triple Negative Breast Neoplasms 64 Endometrial Neoplasms 61 Small Cell Lung Carcinoma 55 Precursor Cell Lymphoblastic Leukemia-Lymphoma 55 Motor Activity 54 Hematologic Neoplasms 54 Disease 54 Glioma 48

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × OTHER × Rare Tumour × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡